1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 8, 6, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Kaposi Sarcoma - Overview
- Kaposi Sarcoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Kaposi Sarcoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Kaposi Sarcoma - Companies Involved in Therapeutics Development
- Amgen Inc
- Aphios Corp
- Bristol-Myers Squibb Co
- Cannabis Science Inc
- Cello Therapeutics Inc
- Codiak BioSciences Inc
- DAE HWA Pharmaceutical Co Ltd
- Eli Lilly and Co
- Galephar Pharmaceutical Research Inc
- Genexine Inc
- Kang Litai Pharmaceutical Co Ltd
- LATITUDE Pharmaceuticals Inc
- LipoSeuticals Inc
- Macrophage Therapeutics Inc
- Merck & Co Inc
- Merck KGaA
- Nammi Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Philogen SpA
- Sanofi
- Seven and Eight Biopharmaceuticals Corp
- Statera Biopharma Inc
- Tumorend LLC
- VasGene Therapeutics Inc
- Kaposi Sarcoma - Drug Profiles
- abemaciclib - Drug Profile
- Product Description
- Mechanism Of Action
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- BDB-001 - Drug Profile
- Product Description
- Mechanism Of Action
- bifikafusp alfa + onfekafusp alfa - Drug Profile
- Product Description
- Mechanism Of Action
- bintrafusp alfa - Drug Profile
- Product Description
- Mechanism Of Action
- CDK-003 - Drug Profile
- Product Description
- Mechanism Of Action
- CE-003 - Drug Profile
- Product Description
- Mechanism Of Action
- CM-101 - Drug Profile
- Product Description
- Mechanism Of Action
- CSTATI-1 - Drug Profile
- Product Description
- Mechanism Of Action
- doxorubicin - Drug Profile
- Product Description
- Mechanism Of Action
- efineptakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- ipilimumab + nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- KLT-1101 - Drug Profile
- Product Description
- Mechanism Of Action
- M-9241 - Drug Profile
- Product Description
- Mechanism Of Action
- metenkefalin - Drug Profile
- Product Description
- Mechanism Of Action
- nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- NTI-1A - Drug Profile
- Product Description
- Mechanism Of Action
- paclitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- paclitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- paclitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- paclitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- pembrolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- SAR-442720 - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile
- Product Description
- Mechanism Of Action
- talimogene laherparepvec - Drug Profile
- Product Description
- Mechanism Of Action
- Vas-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Kaposi Sarcoma - Dormant Projects
- Kaposi Sarcoma - Discontinued Products
- Kaposi Sarcoma - Product Development Milestones
- Featured News & Press Releases
- Apr 11, 2022: Treatment with nivolumab and low-dose ipilimumab is effective and tolerable in patients with previously treated progressive classical kaposi sarcoma
- Jul 26, 2021: NeoImmuneTech receives U.S. FDA IND clearance for phase 1 study of NT-I7 (efineptakin alfa) for the treatment of Kaposi Sarcoma in patients with or without HIV infection
- Apr 10, 2021: Codiak presents data at AACR 2021 demonstrating potential of engineered exosomes to enhance the therapeutic index of well-validated cancer immunotherapy pathways
- Dec 30, 2020: Codiak reports positive initial phase 1 results for exoIL-12 demonstrating tolerability and absence of systemic IL-12 exposure in healthy volunteers
- Dec 21, 2020: New publication in Molecular Cancer Therapeutics highlights data from preclinical development of exoIL-12 for the treatment of cancer
- Nov 09, 2020: Codiak presents preclinical data at SITC 2020 demonstrating potential of engEx engineered exosomes to stimulate targeted, integrated anti-tumor immunity
- Nov 07, 2017: For cancer patients with HIV, immunotherapy appears safe
- May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea
- May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update
- Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi’s Sarcoma
- Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi’s Sarcoma and Tumor Associated Macrophages
- Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
- Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
- Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
- Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Kaposi Sarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Kaposi Sarcoma - Dormant Projects, 2022
- Kaposi Sarcoma - Discontinued Products, 2022
- Number of Products under Development for Kaposi Sarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Aphios Corp
- Bristol-Myers Squibb Co
- Cannabis Science Inc
- Cello Therapeutics Inc
- Codiak BioSciences Inc
- DAE HWA Pharmaceutical Co Ltd
- Eli Lilly and Co
- Galephar Pharmaceutical Research Inc
- Genexine Inc
- Kang Litai Pharmaceutical Co Ltd
- LATITUDE Pharmaceuticals Inc
- LipoSeuticals Inc
- Macrophage Therapeutics Inc
- Merck & Co Inc
- Merck KGaA
- Nammi Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Philogen SpA
- Sanofi.
- Seven and Eight Biopharmaceuticals Corp
- Statera Biopharma Inc
- Tumorend LLC
- VasGene Therapeutics Inc
